These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36880020)

  • 1. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
    Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS
    Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
    Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
    Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
    Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments.
    Hussain RM; Neal A; Yannuzzi NA; Patel KH; Huo S; Hariprasad SM; Bhatia SP
    Ther Adv Ophthalmol; 2021; 13():25158414211055964. PubMed ID: 34926990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients.
    Kin A; Mizukami T; Ueno S; Mishima S; Shimomura Y
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064598
    [No Abstract]   [Full Text] [Related]  

  • 6. Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment.
    Ueji N; Mase Y; Kubo A; Matsubara H; Chujo S; Matsui Y; Kondo M
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893574
    [No Abstract]   [Full Text] [Related]  

  • 7. Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration.
    Kato N; Haruta M; Furushima K; Arai R; Matsuo Y; Yoshida S
    Clin Ophthalmol; 2023; 17():1187-1192. PubMed ID: 37096209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study.
    Hirano T; Kumazaki A; Tomihara R; Ito S; Hoshiyama K; Murata T
    Sci Rep; 2023 Jul; 13(1):10901. PubMed ID: 37407660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
    Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD.
    Kamao H; Mitsui E; Date Y; Goto K; Mizukawa K; Miki A
    J Ophthalmol; 2024; 2024():3673930. PubMed ID: 38322501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.
    Hirono K; Maruyama-Inoue M; Yanagi Y; Kadonosono K
    PLoS One; 2024; 19(4):e0302295. PubMed ID: 38635732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
    Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
    Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema.
    Hirano T; Toriyama Y; Takahashi Y; Hoshiyama K; Murata T
    Am J Ophthalmol Case Rep; 2023 Mar; 29():101788. PubMed ID: 36632338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness.
    Hirayama K; Yamamoto M; Honda S; Kyo A; Misawa N; Kohno T
    J Clin Med; 2024 Jul; 13(15):. PubMed ID: 39124642
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
    Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
    Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.